No, do not give metoprolol (Lopressor) to this patient with NSTEMI and a blood pressure of 98/56 mmHg.
This patient has a clear contraindication to beta-blocker therapy due to hypotension (systolic BP <100 mmHg) and evidence of a low-output state, which places them at increased risk for cardiogenic shock.
Why Beta-Blockers Are Contraindicated in This Scenario
The ACC/AHA guidelines explicitly state that oral beta-blocker therapy should be initiated within the first 24 hours for NSTEMI patients who do NOT have: 1) signs of heart failure, 2) evidence of a low-output state, 3) increased risk for cardiogenic shock, or 4) other relative contraindications 1, 2, 1. Your patient fails this safety screen on multiple counts.
The FDA drug label for metoprolol reinforces this, listing as a contraindication in myocardial infarction: systolic blood pressure <100 mmHg 3. This is not a soft recommendation—it's a hard stop.
Risk Factors for Cardiogenic Shock Present
Your patient has a systolic BP of 98 mmHg, which is specifically identified as a risk factor for cardiogenic shock (systolic BP <120 mmHg increases shock risk) 1. The guidelines note that the COMMIT trial demonstrated that early aggressive beta blockade poses a substantial net hazard in hemodynamically unstable patients, with an increase in cardiogenic shock occurring primarily on the first day, particularly in those who were hemodynamically compromised 1.
What to Do Instead
Immediate Management:
- Stabilize hemodynamics first: Address the hypotension before considering any beta-blocker therapy
- Evaluate for signs of cardiogenic shock: assess for end-organ hypoperfusion, cool extremities, altered mental status, oliguria
- Consider causes of hypotension: right ventricular involvement, hypovolemia, bleeding, medication effects
- Nitroglycerin should also be avoided or used with extreme caution given the BP <100 mmHg 1, 2
Reassessment Strategy:
- Patients with an initial contraindication to beta-blocker therapy can be reassessed after 24 hours and initiated on oral beta-blocker therapy if the contraindication has resolved 4
- Once the patient is hemodynamically stable with systolic BP consistently >100 mmHg and no signs of low output, oral beta-blockers can be cautiously initiated
- Start with low doses and titrate gradually
Alternative Anti-Ischemic Therapy:
If ongoing ischemia is present and beta-blockers remain contraindicated:
- Consider a nondihydropyridine calcium channel blocker (verapamil or diltiazem) once hemodynamically stable, provided there is no clinically significant LV dysfunction 1, 2, 1
- Optimize other guideline-directed medical therapy that is safe in this BP range
Common Pitfall to Avoid
The most dangerous error here would be reflexively administering beta-blockers simply because the patient has NSTEMI, without checking for contraindications. The guidelines are clear that beta-blockers should be avoided with hemodynamic instability 1. The COMMIT trial's findings of increased early cardiogenic shock with IV metoprolol in compromised patients fundamentally changed practice—this is why current guidelines emphasize oral administration in stable patients only 1.
Bottom line: Stabilize the blood pressure first, then reassess for beta-blocker eligibility once systolic BP is consistently ≥100 mmHg and the patient shows no signs of low cardiac output or impending shock.